PD-1/PD-L1 has been explored in the setting of NKTCL, with reports of PD-L1 expression in various cohorts to range between 38 to 93% (68, 178), and the usage of PD-1 inhibitors such as pembrolizumab has shown promising results in the setting of R/R NKTCL (121, 122). Here, PDCD1 is linked to extranodal nasal NK/T cell lymphoma.